Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duck reovirus inactivated vaccine (strain TH11)
- Development stage
- Preclinical
- Lead developer
- Spirit Jinyu Biological Pharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The duck reovirus inactivated vaccine (strain TH11) is a veterinary biologic developed by Spirit Jinyu Biological Pharmaceutical for the prevention of novel duck reovirus (NDRV) infections in avian species, particularly ducks. This vaccine utilizes the TH11 strain of the virus, which is inactivated to eliminate pathogenicity while preserving its ability to stimulate the host's immune system. NDRV is characterized by severe hemorrhagic and necrotic lesions in the liver and spleen, leading to high mortality rates in young ducklings and substantial economic impact on the poultry industry. The vaccine is currently in the IND-enabling phase of development, intended to provide protective immunity through the exposure of killed viral particles to the avian immune system.
- Other names
- Duck Reovirus Inactivated Vaccine TH11Novel Duck Reovirus Inactivated Vaccine (Strain TH11)
Beyond the preview
Go deeper on duck reovirus inactivated vaccine (strain TH11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duck reovirus inactivated vaccine (strain TH11).